Labcorp Teams With Grupo Fleury on Brazil Trials

The collaboration aims to expand clinical trial operations in Brazil through a two-stage build-out with Fleury's São Paulo facilities.

Updated on Nov. 18, 2026 in Corporate Finance

Isometric editorial illustration of identical sealed cases stacked on a pale shelf beside one open case with empty compartments, in muted teal, cream, and slate tones.
Labcorp said on Tuesday it will expand clinical trial operations in Brazil with Grupo Fleury, building out local trial-kit assembly in 2027 before adding lab testing at Fleury's São Paulo facilities by late 2027. AI Illustration. Upload story photo >

Labcorp announced a collaboration with Grupo Fleury to build out clinical trial operations in Brazil, structured in two stages. The deal disclosed no contract value, equity stake, or exclusivity term.

Why it matters

Brazil reportedly climbed to 12th place worldwide for newly initiated clinical studies in early 2026, and Labcorp said sponsors increasingly need partners that pair global reach with local regulatory knowledge. For international investors, the move signals how laboratory and trial service providers are expanding into fast-growing emerging markets.

Labcorp reported $3.81bn in revenue and $262.8m in net income for the three months to 30 September 2026, with shares closing at $368.24 on announcement day within a twenty-session range of $351.875 to $373.30. The financial terms of the Brazil collaboration, including any contract value, remain undisclosed.

The players

Labcorp

Labcorp is a major American clinical laboratory and diagnostics company that provides testing services to healthcare providers, pharmaceutical sponsors, and patients worldwide.

Grupo Fleury

Grupo Fleury is a large Brazilian diagnostics and laboratory group headquartered in São Paulo that operates clinical testing services across the country.

The details

Under the first stage, dedicated local assembly of clinical trial kits is to be established in Brazil, with work expected to begin in early 2027. A second phase brings specialised laboratory testing onto Fleury's facilities in São Paulo, currently pencilled in for the end of 2027.

Timeline

  1. 30 September 2026: Labcorp's latest reported quarter closes with revenue of $3.81bn.

  2. 17 November 2026: Short-sale volume ratio reaches 0.685, per FINRA data.

  3. 18 November 2026: An insider Form 4 is filed for Amy B. Summy.

  4. Early 2027: Clinical trial kit assembly in Brazil is expected to begin.

  5. End of 2027: Laboratory testing at Fleury's São Paulo facilities is planned.

Market Dynamics

Brazil's climb to 12th place worldwide for newly initiated clinical studies in early 2026 signals growing sponsor demand in Latin America. Labcorp's move to build local trial operations positions it to capture that expanding pipeline against regional rivals.

Investors tracking Labcorp should note that the financial terms of the Brazil collaboration remain undisclosed and no Form 8-K has been filed. Shareholders may watch upcoming quarterly results for any revenue contribution from the Brazil expansion.

The takeaway

Expansion into emerging clinical trial markets like Brazil is becoming a competitive priority for diagnostics providers. Readers following the sector should track whether these staged partnerships produce disclosed financial results.

Further reading

For broader context on company deal-making, explore Corporate Finance coverage.

Source note: This article includes information reported by ABC Money.